Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Braz. j. infect. dis ; 23(1): 34-39, Jan.-Feb. 2019. tab, graf
Article in English | LILACS | ID: biblio-1001496

ABSTRACT

ABSTRACT Background: Hepatitis C is an important health problem. In Brazil, 1-2 million people are infected. Despite this expressive number, and the availability of very successful treatment, many patients remained undiagnosed mainly because of the asymptomatic nature of the infection. Objectives: To describe epidemiological characteristics of HCV-infected patients seen at referral centers in Brazil, the source of referral, and the time spanned to reach a reference center, in order to improve the identification of undiagnosed patients. Methods: Multicenter observational, cross-sectional study carried out in 15 centers of Brazil, between January/2016 and June/2017. Data of patients with a confirmed diagnosis (anti-HCV and HCV-RNA) were collected by interview using standard questionnaires and by review of charts. Results: Two thousand patients were included; 55.1% were male, mean age 58 ± 11 years. Only 14.9% had higher education and 84.2% received up to five monthly minimum Brazilian wages (approximately US$260.00/month). The time between diagnosis and beginning of follow-up was 22.9 months. The most common reasons for testing were check-up (33.2%) and blood donation (19%). General practitioners diagnosed most of the patients (30.1%). Fibrosis stage was mainly evaluated by liver biopsy (61.5%) and 31.3% of the patients were cirrhotic at diagnosis. Conclusions: This multicenter Brazilian study showed that the mean time to reach a referral center for treatment was almost two years. Primary care physicians diagnoses most hepatitis C cases in the country. Population campaigns and medical education should be encouraged to intensify screening of asymptomatic individuals, considering the efficiency of check-ups in identifying new patients.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/epidemiology , Socioeconomic Factors , Time Factors , Brazil/epidemiology , Cross-Sectional Studies , Sex Distribution
2.
Ann. hepatol ; 16(2): 255-262, Mar.-Apr. 2017. tab, graf
Article in English | LILACS | ID: biblio-887230

ABSTRACT

ABSTRACT Background. Hepatocellular carcinoma (HCC) is the most common malignancy that develops in cirrhotic livers. Its clinical and epidemiological characteristics and mortality rates vary according to geographical region. The objective of this study was to evaluate the clinical profile, epidemiological characteristics, laboratory parameters, treatment and survival of patients with HCC. Material and methods. Patients with HCC seen between 2000 and 2012 were studied. The Kaplan-Meier method was used for survival analysis according to variables in question. Results. The study included 247 patients with a mean age of 60 ± 10 years. There was a predominance of males (74%). The main etiologies of HCC were HCV infection (55%), excessive alcohol consumption (12%), and HBV infection (8%). Liver cirrhosis was present in 92% of cases. The mean tumor number and diameter were 2 and 5 cm, respectively. Patients meeting the Milan criteria corresponded to 43% of the sample. Liver transplantation was performed in 22.4% of patients of the Milan subset and in 10% of the whole sample. The overall mean survival was 60 months, with a 1-, 3- and 5-year survival probability of 74%, 40% and 29%, respectively. Lower survival was observed among patients with alcoholic etiology. Survival was higher among patients submitted to liver transplantation (P < 0.001), TACE (P < 0.001), or any kind of treatment (P < 0.001). However, no difference was found for surgical resection (P = 0.1) or sorafenib (P = 0.1). Conclusion. Patients with HCC were mainly older men diagnosed at an advanced stage. Treatment was associated with better overall survival, but few patients survived to be treated.


Subject(s)
Humans , Liver Transplantation , Chemoembolization, Therapeutic , Carcinoma, Hepatocellular/therapy , Ablation Techniques , Hepatectomy , Liver Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Phenylurea Compounds/therapeutic use , Time Factors , Brazil/epidemiology , Risk Factors , Treatment Outcome , Chemoembolization, Therapeutic/adverse effects , Chemoembolization, Therapeutic/mortality , Niacinamide/analogs & derivatives , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Tumor Burden , Kaplan-Meier Estimate , Tertiary Care Centers , Hepatectomy/adverse effects , Hepatectomy/mortality , Liver Neoplasms/etiology , Neoplasm Staging , Antineoplastic Agents/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL